Additionally, MMP9 is upregulated in breast, prostate cancers [58], bladder cancer [59], and colorectal cancer [60], suggesting that the upregulation of MMP9 may be influenced by the overexpression of these co-activators. This evidence concerns the gene MMP9 and urinary bladder carcinoma.